ENTA

7.6204.51%
BL

Bruce Leonard Andrews Carter

Independent Non-Executive Chairman

Dr. Bruce Leonard Andrews Carter, Ph.D., is Chairman of KayoThera, Inc. from July 2025. He serves as the Executive Chairman of The Global Alliance for TB Drug Development. Dr. Carter serves as an Affiliate Professor, Department of Biochemistry at the University of Washington, Seattle, Washington since 1986. He has been Independent Chairman of the Board at ALSP Orchid Acquisition Corporation I since November 2021. Dr. Carter has extensive governing experience as an executive and leader in the pharmaceutical and biotechnology industries. He served as the Chief Executive Officer at ZymoGenetics, Inc. from April 1998 to January 2009 and Chairman of the Board from April 2005 to October 2010 and previously from 1994 to December 1998. Dr. Carter served as President of ZymoGenetics, Inc. from April 1998 to July 2, 2007 and previously from 1988 to 1995. He led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk in 2000. From 1994 to April 2000, he served as a Corporate Executive Vice President and Chief Scientific Officer for Novo Nordisk A/S, the former parent company of ZymoGenetics. He served on the Board of Management of Biothera Holding Corp. and Novo Nordisk from 1988 to 2000. From 1982 to 1986, he served various positions at G.D. Searle & Co. Ltd., including Head of Molecular Genetics. Previously he held positions in research at ZymoGenetics and G.D. Searle & Co. Ltd. He joined ZymoGenetics in 1986 as Vice President of Research and Development. He served as Executive Chairman of Immune Design Corp. from November 2009 to November 2011. He serves as a Senior Advisor of Accelerator Life Sciences Partners since October 2016 and was an Independent Board Member at the firm. Dr. Carter serves as a Director on the Boards of Accelerator portfolio companies He has been an Independent Non-Executive Chairman at Enanta Pharmaceuticals, Inc. since December 14, 2015. He has been Independent Director at Aurigene Discovery Technologies Limited since 2018. He served as the Chairman of the Board of Xencor, Inc. since December 2009 until June 22, 2017. He served as the Chairman of the Board at Fisher BioImage ApS. He served as Deputy Chairman of Supervisory Board of Epigenomics AG since September 1, 2004. He had been an Independent Director of Mirati Therapeutics, Inc. since September 29, 2016 until January 23, 2024. He serves as Director at Metheor Therapeutics Corp. He had been an Independent Non-Whole Time Director of Dr. Reddy’s Laboratories Ltd. since July 21, 2008 until July 30, 2022. Dr. Carter holds Directorship in Accelerator IV-Seattle Corporation. He has been a Director of TB Alliance, LION Bioscience, Inc. since March 2000 and Evotec (US), Inc. since April 23, 2005. He has been an Independent Director of Enanta Pharmaceuticals, Inc. since November 2013. He serves as a Director of Fisher BioImage ApS, Biothera Holding Corp., Washington Biotechnology & Biomedical Association and Reddy US Therapeutics Inc., Skele Tech Inc. and Biotechnology Innovation Organization (BIO). He has been an Independent Director at Xencor since September 2009. He served as a Director of Biothera, Inc. since February 5, 2014. He served as a Director of Regulus Therapeutics Inc. since June 2012 until November 24, 2015. He served as a Director of Immune Design Corp. from 2000 to January 2009. He served as a Director of moksha8 Pharmaceuticals Inc. He served as a Director at Sarepta Therapeutics, Inc. from 1998 to March 18, 2003 and Anergen Incorporated since February 1994. He served as a Director of ZymoGenetics Inc. since 1987. He served as a Non-Executive Director of Ark Therapeutics Group plc from July 7, 2005 to April 24, 2008. He served as a Director of QLT Inc. from November 29, 2006 to June 4, 2012. He served as a Director at SkeleTech, Inc. He served as a Member of Supervisory Board of Epigenomics AG until March 30, 2007. He is Board Chair of the Infectious Disease Research Institute. He was a Lecturer of Trinity College, University of Dublin from 1975 to 1982. Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.

Positions